MAPT and Alzheimer disease: For this reason, it was deemed advantageous to combine the measurement of Aβ40, Aβ42, and tau in CSF to confirm AD in patients, and it was hoped that these measurements would be a useful biological marker for AD therapeutic strategies [41].